Intensity Therapeutics (INTS) announces that INT230-6 achieved complete responses in a murine models of Malignant Peripheral Nerve Sheath Tumor. In a study conducted in the Staedtke-Bai laboratory at Johns Hopkins University, at 21 days, animals tested with INT230-6 all achieved a complete response, whereas all animals’ tumors in the control group continued to grow.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.